Research and Markets: Triple Analysis: an Extensive Analysis on Cancer Drug Development Strategies in Leukemia, Pancreatic Cancer and Antibodies

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c8b2a0/triple_analysis_l) has announced the addition of the "Triple Analysis: Leukemia, Pancreatic Cancer and Antibodies" report to their offering.

“Triple Analysis: Leukemia, Pancreatic Cancer and Antibodies”

This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia The leukemia report part comprises defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. This report part extensively analyses 136 identified targets of leukemia drugs, organized into 115 drug target strategies, and assesses them in leukemia.

Part II: Pancreatic Cancer The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

Part III: Antibodies The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by:

• Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
• Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties
• Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
• Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
• Supporting development of integrative molecule, pathway and disease area strategies
• Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia

Part II: Pancreatic Cancer

Part III: Antibodies

For more information visit http://www.researchandmarkets.com/research/c8b2a0/triple_analysis_l